首页> 外文期刊>Nuclear Medicine and Biology >Tumor uptake of radioiodinated anti-human pulmonary surfactant-associated protein monoclonal antibody PE10 in nude mice bearing human pulmonary adenocarcinoma in combination with an unlabeled preload
【24h】

Tumor uptake of radioiodinated anti-human pulmonary surfactant-associated protein monoclonal antibody PE10 in nude mice bearing human pulmonary adenocarcinoma in combination with an unlabeled preload

机译:放射性碘标记的抗人肺表面活性剂相关蛋白单克隆抗体PE10在人肺腺癌裸鼠中结合未标记的预负荷

获取原文
获取原文并翻译 | 示例
           

摘要

This study assessed the potential use of radioimmunoscintigraphy of pulmonary alveolar Type II cells tumor with the radiolabeled anti human surfactant associated protein (SP) monoclonal antibody (MAb) PE 10 in combination with preloads of unlabeled MAb. The in vitro binding of iodine-125 (I-125)-labeled MAb PE 10 (1 mug), which had a specific radioactivity of 400 MBq/mg, on human pulmonary papillary adenocarcinoma NCI-H441 cells that produced SP was investigated. In NCI-H441 tumor-bearing nude mice, the tumor uptake of I-125-MAb PE 10 (5 mug) was examined in combination with preloads of unlabeled MAb PE 10 (0, 5, 10, and 50 mug). An isotype matched unassociated murine MAb was used as a control both in vitro and in vivo. I-125-MAb PE 10 showed specific cell binding compared with I-125 control MAb. Tumor uptake of I-125-MAb pE 10 in vivo reached a peak of 4.97 +/- 0.33% injected dose per gram (%ID/g) at 48 h postinjection. Preloads of 5 and 10 mug unlabeled MAb PE 10 significantly enhanced tumor uptake at 48 h postinjection (5.94 +/- 0.29% ID/g and 5.72 +/- 0.29% ID/g, respectively), whereas preload of 50 mug unlabeled MAb PE 10 significantly decreased tumor uptake (2.75 +/- 0.32% ID/g) at 48 h. Preload of 5 mug unlabeled MAb PE 10 significantly increased the tumor-to-blood radioactivity ratio at 48 h (2.39 +/- 0.16). Preloads of unlabeled control MAL, did not cause any significant change in tumor uptake. Immunohistochemistry showed the intracellular and pericellular patterns of SP expression in tumor cells. In conclusion, radioimmunoscintigraphy with MAb PE 10 labeled with a gamma -emitting radioiodine such as I-123 might be a useful means of targeting pulmonary alveolar Type II tumor cells in combination with preloading with an optimal dose of the unlabeled MAb. NUCl MED BIOL 27;8:723-731, 2000. (C) 2000 Elsevier Science Inc. All rights reserved. [References: 21]
机译:这项研究评估了放射性标记的抗人表面活性剂相关蛋白(SP)单克隆抗体(MAb)PE 10与未标记的MAb的预加量结合使用对肺泡II型细胞肿瘤进行放射免疫闪烁成像的潜在用途。研究了碘125(I-125)标记的MAb PE 10(1杯)的体外结合在人肺乳头状腺癌NCI-H441细胞上的结合,该放射性活度为400 MBq / mg。在带有NCI-H441荷瘤的裸鼠中,结合未标记的MAb PE 10(0、5、10和50马克杯)的预负荷,检查了I-125-MAb PE 10(5马克杯)的肿瘤吸收。同种型匹配的未结合鼠单克隆抗体在体外和体内均用作对照。与I-125对照MAb相比,I-125-MAb PE 10显示出特异性的细胞结合。注射后48小时,体内I-125-MAb pE 10的肿瘤吸收达到每克注射剂量4.97 +/- 0.33%(%ID / g)的峰值。 5和10杯未标记MAb PE 10的预加载可显着提高注射后48小时的肿瘤吸收(分别为5.94 +/- 0.29%ID / g和5.72 +/- 0.29%ID / g),而50杯未标记MAb PE的预加载10在48 h时肿瘤吸收显着降低(2.75 +/- 0.32%ID / g)。预装5杯未标记的MAb PE 10在48 h时显着提高了肿瘤与血液的放射性比(2.39 +/- 0.16)。未标记的对照MAL的预载量不会引起肿瘤吸收的任何显着变化。免疫组织化学显示肿瘤细胞中SP表达的细胞内和细胞外模式。总而言之,用预发射最佳剂量未标记MAb结合的用伽马发射放射性碘(例如I-123)标记的MAb PE 10进行放射免疫闪烁成像可能是靶向肺泡II型肿瘤细胞的有用手段。 NUCl MED BIOL 27; 8:723-731,2000.(C)2000 Elsevier Science Inc.保留所有权利。 [参考:21]

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号